Figure S1 Forest plot indicating the odds ratio of the occurrence of lymphoceles in kidney transplant recipients on mTOR inhibitors plus antimetabolites.

Figure S2 Forest plot indicating the odds ratio of the occurrence of wound complications in heart transplant recipients on mTOR inhibitors plus CNIs.

Table S1. mTOR inhibitors plus belatacept in kidney transplantation (n=1).

Table S2. mTor inhibitors plus CNIs for heart transplantation (n=4).

Table S3. mTOR inhibitors in liver transplantation (n=1).

Table S4. mTor inhibitors in simultaneous pancreas kidney transplantation (n=1).

Table S5. RCTs that investigated mTOR inhibitors combined with steroids versus no steroids in kidney transplantation (n=2).

Table S6. Description of wound-related events and whether lymphoceles were reported for each RCT included in the systematic review.

Table S7. Subgroup analysis for RCTs of good methodological quality, i.e., adequate allocation concealment or a total Jadad score of at least three for RCTs in kidney transplantation. The number of trials refers to the number of RCTs that were of good methodological quality according to each of the quality criteria including the total number of patients included in the analysis.

TRI_1357_sm_TableS1-S7.doc214KSupporting info item
TRI_1357_sm_figure1.jpg1390KSupporting info item
TRI_1357_sm_figure2.jpg1021KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.